Axon degeneration is an intrinsic self-destruction program that underlies axon loss during injury and disease. Sterile alpha and TIR motif-containing 1 (SARM1) protein is an essential mediator of axon degeneration. We report that SARM1 initiates a local destruction program involving rapid breakdown of nicotinamide adenine dinucleotide (NAD + ) after injury. We used an engineered protease-sensitized SARM1 to demonstrate that SARM1 activity is required after axon injury to induce axon degeneration. Dimerization of the Toll-interleukin receptor (TIR) domain of SARM1 alone was sufficient to induce locally mediated axon degeneration. Formation of the SARM1 TIR dimer triggered rapid breakdown of NAD + , whereas SARM1-induced axon destruction could be counteracted by increased NAD + synthesis. SARM1-induced depletion of NAD + may explain the potent axon protection in Wallerian degeneration slow (Wld s ) mutant mice.
C ells undergo regulated self-destruction during development and in response to stresses (1) . Axons, the longest cellular structures in the body, have a locally mediated selfdestruction program that removes damaged axons but also promotes axon loss in the setting of neurological disorders (2) . Axon degeneration is antagonized by the Wallerian degeneration slow (Wld s ) chimeric protein (3) . The active moiety of Wld s is the enzyme nicotinamide mononucleotide adenyltransferase 1 (Nmnat1), which synthesizes the essential cofactor nicotinamide adenine dinucleotide (NAD + ) (4) , but the function of Nmnat1 and NAD + in axon protection remains unclear (2) . The protein SARM1 (sterile alpha and TIR motif-containing 1; TIR, Toll-interleukin receptor) is an essential mediator of axon degeneration (5, 6) . SARM1 is a negative regulator of Toll-like receptor-activated transcriptional programs (7) , but its mechanism for axon degeneration is unknown.
To investigate whether SARM1 functions before or after injury, we engineered a system to inactivate SARM1 with pharmacologic control. Protease-sensitized SARM1 (SARM ps ) contains a tobacco etch virus (TEV) protease consensus sequence between the sterile alpha motif (SAM) and TIR domains, which are both essential for SARM1 function (6) . SARM ps is thus cleaved and inactivated by TEV protease. SARM ps was fused to the rapamycin-binding domain Frb and the N-terminal portion of split TEV protease (Ntev) (8) and coexpressed with C-terminal split TEV fused to FK866 binding protein (Fkbp-Ctev), allowing rapamycin-induced cleavage (Fig. 1A and  fig. S1 ). In dorsal root ganglion (DRG) neurons, cleavage of SARM ps was mostly complete within 60 min of rapamycin treatment (Fig. 1B and  fig. S2A ). SARM ps functionality was verified by expression of SARM ps in isolated Sarm1 −/− DRG neurons. When Sarm1 −/− axons were severed (diagrammed in Fig. 1C ), they remained intact after 24 hours, whereas axons of neurons expressing SARM ps showed degeneration measured by axon morphometry (Fig. 1D ), similar to wild-type axons. SARM ps function was lost upon cleavage triggered by rapamycin in the presence of Fkbp-Ctev (Fig. 1, D and E) or by expression of full-length TEV ( fig. S2B ). Cleavage of SARM ps initiated 12 hours before or up to 2 hours after axon transection fully suppressed axon degeneration measured 24 hours after axotomy. Because cleavage of SARM ps after axons were disconnected from cell bodies resulted in protection, SARM1 must function after injury to promote degeneration. SARM1 has no predicted enzymatic function but contains a TIR domain, which is the effector domain of Toll-like receptors (TLRs). Activation of TLRs results in dimerization of TIR domains that transmit a signal to cytosolic effector proteins (9) . We tested whether multimerization of the TIR domain of SARM1 (sTIR) might induce axon degeneration. A minimal region of human SARM1 comprising sTIR and the adjacent multimerization (SAM) domains, but lacking the autoinhibitory N terminus (SAM-TIR), is constitutively active and promotes cell and axon destruction in cultured DRG neurons (6) . Expression of this activated form of SARM1 in vivo in Drosophila motor ( Fig. 2A) or sensory neurons ( fig. S3 ) also caused cell and axon destruction. This degeneration was not observed in Drosophila expressing SAM-TIR harboring a disruptive sTIR mutation.
To evaluate the sufficiency of sTIR dimerization in axon destruction, we engineered a pharmacologically controlled dimerizable sTIR by fusing it to the rapamycin-binding domains Frb and Fkbp (Fig. 2B) (10) . We expressed Frb-sTIR and Fkbp-sTIR in DRG neurons and found that sTIR dimerization by rapamycin induced axon fragmentation within 12 hours (Fig. 2C ) and neuronal cell death within 24 hours (Fig. 2D) . sTIRinduced toxicity did not require the inhibition of mammalian target of rapamycin (mTOR), because the rapamycin analog AP20187, which does not target mTOR, also stimulated axon degeneration in cells expressing the homodimerizable Fkbp F36V -sTIR (10) . SARM1 activation is thus sufficient to elicit axonal and neuronal destruction. Cell and axon degeneration were not induced upon dimerization of the TIR domains of TLR4 or the adaptor MYD88 (Fig. 2E) .
We tested whether SARM1 promotes axon degeneration through a local mechanism. sTIRinduced degeneration does not require a physical connection between the axon and soma: Sarm1 −/− axons persisted after severing; however, sTIR dimerization by AP20187 caused fragmentation of these severed segments within 12 hours (Fig.  2F) . Dimerization of sTIR locally within axons also led to selective axon destruction. We grew DRG neurons in adjacent fluid compartments: one containing the cell bodies and proximal axons and the other containing only distal axons (Fig.  2G) . Application of AP20187 to both compartments led to destruction of proximal and distal axons, whereas selective application to the distal chamber elicited selective distal axon degeneration after 24 hours (Fig. 2G ). SARM1 TIR dimerization elicited rapid pathophysiologic changes: Axon degeneration and neuronal death were evident within 1.5 and 6 hours, respectively ( fig. S4, A and B) , and neuronal mitochondrial membrane potential dissipated and calcium accumulated with similar kinetics (fig. S4, C to E). These measurements indicate early energetic failure. We thus focused on biochemical events leading from SARM1 activation to axonal demise. Axon degeneration is antagonized by the NAD + synthetic enzyme Nmnat1, which, like SARM1, functions locally within axons (11) . Injured axons exhibit declining levels of NAD + before morphologic changes (12) (Fig. 3D ). The abundance of ATP also declined after sTIR dimerization, but its depletion was slower than that of NAD + . Together these data implicate NAD + loss as a critical step in SARM1-mediated axon destruction. We therefore examined whether increased NAD + synthesis could counteract the destruction program activated by sTIR dimerization. In DRG neurons, both axon degeneration and cell death initiated by sTIR dimerization were completely blocked by the expression of Nmnat1 and nicotinamide phosphoribosyltransferase (Nampt), which together synthesize NAD + (Fig. 3A) . Protection appeared to require NAD + synthesis, because concurrent treatment with the Nampt inhibitor FK866 blocked the protection afforded by these enzymes (Fig. 3, E and F) . Similarly, sTIR-induced axon degeneration and cell death were blocked by supplementation with the cellpermeant NAD + precursor nicotinamide riboside (NR) (Fig. 3, G and H) (14) . Drosophila larvae expressing the dimerizable Fkbp F36V -sTIR in motor neurons that were fed AP20187 showed extensive axon degeneration that was blocked by coexpression of cytosolic Nmnat1 (Fig. 3I) .
To extend our analysis of biochemical events after SARM1 activation, we created a heterologous human embryonic kidney (HEK293T) cell line (HTir) that stably expresses Frb-sTIR and Fkbp-sTIR. After 12 hours of sTIR dimerization in HTir cells, toxicity was evident, as indicated by the loss of ATP ( fig. S6A ) and altered morphology ( fig. S6B ). Both effects were blocked by NR supplementation. Inhibition of NAD + synthesis with FK866 increased the loss of ATP, whereas FK866 was not toxic in the absence of sTIR dimerization ( fig. S6, A and B) . wild type Sarm1-/- To evaluate whether NAD + depletion alone is sufficient to induce axon destruction, we stimulated direct intracellular breakdown of NAD + by dimerization of the poly-ADP-ribose polymerase (PARP) domain of Tankyrase 1 (Tnkp; diagrammed in Fig. 4A ). We generated dimerizable Fkbp F36V -Tnkp and showed that AP20187 treatment of cells expressing this construct led to loss of NAD + and formation of PAR ( fig. S7, A and B) . In the presence of FK866, which inhibits de novo NAD + synthesis, Tnkp dimerization in dividing cells led to rapid energetic failure (ATP loss) that was blocked by the Tankyrase inhibitor XAV939 (fig.  S7C ). NR supplementation blocked toxicity but not PAR formation, indicating that NAD + loss and not PAR formation caused cell death ( fig. S7 , A and C). In neurons, Tnkp-induced depletion of NAD + caused degeneration of uninjured wildtype and Sarm1 −/− axons (Fig. 4, B and C) . Moreover, NAD + depletion from isolated (presevered) Sarm1 −/− axons led to degeneration (Fig. 4C) . Thus, rapid NAD + depletion is sufficient to cause rapid axon loss.
To define whether SARM1-mediated depletion of NAD + results from increased consumption or decreased synthesis of NAD + , we introduced exogenous NAD + and, as a control, nicotinic acid adenine dinucleotide (NaAD) into HTir cells by electroporation (15) , followed by sTIR dimerization. Control cells showed rapid loss of endogenous NAD + within 5 min in response to sTIR dimerization. Electroporation in the presence of NAD + increased the concentration of NAD + by a factor of 4.3, but NAD + was rapidly consumed upon sTIR dimerization. The specificity of this reaction is highlighted by the stability of the closely related analog NaAD (Fig. 4D) (Fig. 4E) . Similarly, sTIR dimerization in nonelectroporated cells also elicited Nam release as detected by HPLC (fig. S8) .
Rapid breakdown of NAD + induced by SARM1 TIR is similar to that observed when PARP is activated in response to DNA damage (16) . However, NAD + breakdown induced by sTIR is PARPindependent. The PARP inhibitor olaparib reduced NAD + loss induced by H 2 O 2 , but had no effect on SARM1-induced loss of NAD + (Fig. 4F ). Furthermore, H 2 O 2 led to PARP-dependent accumulation of PAR, whereas no PAR was detected after sTIR dimerization (Fig. 4F) Protein synthesis rates can affect gene expression and the folding and activity of the translation product. Interactions between the nascent polypeptide and the ribosome exit tunnel represent one mode of regulating synthesis rates. The SecM protein arrests its own translation, and release of arrest at the translocon has been proposed to occur by mechanical force. Using optical tweezers, we demonstrate that arrest of SecM-stalled ribosomes can indeed be rescued by force alone and that the force needed to release stalling can be generated in vivo by a nascent chain folding near the ribosome tunnel exit. We formulate a kinetic model describing how a protein can regulate its own synthesis by the force generated during folding, tuning ribosome activity to structure acquisition by a nascent polypeptide.
T he ribosome translates mRNA into amino acid sequences that contain the information needed for the polypeptide to attain its native structure. Differential usage of synonymous codons and structural elements in the mRNA modulate polypeptide elongation rates. Such rate variations may be required for proper folding and processing of nascent proteins (1) . Moreover, interactions of specific nascent chain sequences (2, 3) with the ribosome exit tunnel (4) result in reduced rates of elongation. The bacterial SecM protein represents an example of a stalling sequence that interacts with the ribosome exit tunnel and allosterically represses the peptidyl transferase activity of the ribosome (4-7). Translation of SecM regulates expression of SecA, the motor component of the bacterial Sec translocon (2) . Release of stalling in vivo requires interactions between nascent SecM and the translocon machinery (8, 9) . It has been suggested that mechanical force exerted by the translocon relieves elongation arrest and leads to translation restart (10) .
To investigate the effect of force on the release of SecM-stalled ribosome-nascent chains (RNCs), we adapted a single-molecule optical tweezers assay (11) (Fig. 1A) , enabling the application of defined forces to single ribosomeassociated nascent polypeptides. We generated stalled RNCs that contained the C-terminal domain of human calmodulin (CaM) (figs. S1 and S2). CaM provides a mechanical fingerprint (12) in our experiments by exhibiting equilibrium folding and unfolding ("hopping") at~7 pN (Fig. 1B and supplementary materials) . To detect release of stalled ribosomes, we used the antibiotic puromycin. Puromycin binds to the ribosomal A site and is incorporated into the nascent polypeptide, leading to its release from the ribosome (13) . SecM-arrested ribosomes, containing a prolyl-tRNA pro stably bound in the A site, are refractory to treatment with puromycin, but become sensitive after arrest release, proline incorporation, and translocation (14) (figs. S3 and S4). In the presence of puromycin and EF-G, arrest release will become apparent as a rupture of the tether (Fig. 1B and fig. S4 ).
We applied a defined, constant force to the molecule in the range of 10 to 30 pN and measured the time required to restart translation, as measured by tether rupture. The mean restart times decreased with increasing force (Fig.  1C) . We calculated the rate of stalling rescue as a function of the applied force (Fig. 1, C ). This rate is in agreement with biochemical ensemble experiments, in which no force was applied (Fig. 1D, blue dot and fig. S3 ). In the force range of our experiments, release of SecMmediated arrest is accelerated by more than an order of magnitude (Fig. 1D) , supporting the hypothesis that SecM arrest is relieved by the mechanical force generated by the SecA adenosine triphosphatase (ATPase).
Cotranslational insertion of transmembrane helices via the translocon can release SecMmediated stalling, presumably by generating force (16) . We wondered whether folding of a nascent globular protein domain could generate a force capable of modulating elongation by acting on peptide-tunnel interactions. Such interactions could serve to tune elongation rates to folding transitions (3, 4) . The exit tunnel is too narrow to accommodate folded protein domains (17) ; therefore, as a nascent polypeptide emerges from the exit tunnel and folds in close proximity to the ribosome, it will be sterically excluded from the tunnel. This steric exclusion might generate a force that pulls on the nascent chain within the exit tunnel, which could modulate ribosome activity.
Having established that force accelerates SecM arrest release, we used SecM as a sensor to detect if nascent protein folding outside the ribosome can release the arrest. We constructed a library of plasmids encoding fusion proteins in which the stalling sequence (SecM17) is separated from the de novo-designed protein Top7 (18) by flexible linker sequences of various lengths, followed by a reporter green fluorescent protein (GFP) (Fig. 2A, fig. S7 , and supplementary materials). Top 7 folds rapidly against an applied force in close proximity to the ribosome ( fig. S8 ). The GFP coding sequence is translated only upon successful release of the SecM17-mediated translation arrest. Variations in the length of the linker separating Top7 and SecM17 would affect the translation outcome of these constructs (Fig. 2B ). Short linker sequences will not allow folding of Top7 because the C terminus of the protein will be sequestered in the exit tunnel (Fig. 2B, top) . Intermediate-length linkers will allow more of the Top7 sequence to emerge from the ribosome tunnel and for the protein to fold and produce the steric exclusion folding force (Fig. 2B, middle) . And while longer
